Literature DB >> 10494495

Comparative study of self-rating pain scales in rheumatoid arthritis patients.

N Bellamy1, J Campbell, J Syrotuik.   

Abstract

Although progress has been made in the clinical metrology of pain in rheumatoid arthritis, much further work remains. The preferred methods of measurement remain debatable. In this longitudinal, open study, a comparison of eight self-rating pain scales has been conducted. A total of 124 patients entered the four-week study after completing a 3-7-day NSAID-free washout period. Patients were assigned to treatment with oxaprozin 1200 mg p.o. once daily with titration permitted between 600 mg and 1800 mg. Rescue analgesia with acetaminophen (paracetamol) 325 mg (maximum 2600 mg) was permitted. At the end of the washout and treatment period, patients completed eight self-administered pain rating scales. All pain measures detected clinically important and statistically significant improvements in pain. The pain scales differed in their degree of responsiveness. The Likert and visual analogue scales and their primary variations (continuous chromatic analogue and numerical scales) were more responsive than more complex measures. A positive correlation between initial pain rating and subsequent pain response was confirmed in this study. We conclude that, while pain is a subjective sensory phenomenon, its perceived severity can be evaluated using a variety of self-administered pain scales, all of which are capable of detecting improvements in health status following effective pharmacological intervention.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10494495     DOI: 10.1185/03007999909113372

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  8 in total

Review 1.  Science of assessment.

Authors:  N Bellamy
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 2.  A systematic review of measures used to assess chronic musculoskeletal pain in clinical and randomized controlled clinical trials.

Authors:  Leighann Litcher-Kelly; Sharon A Martino; Joan E Broderick; Arthur A Stone
Journal:  J Pain       Date:  2007-08-09       Impact factor: 5.820

3.  Sensitivity to change of AIMS2 and AIMS2-SF components in comparison to M-HAQ and VAS-pain.

Authors:  E Taal; J J Rasker; R P Riemsma
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

4.  Definition of nonresponse to analgesic treatment of arthritic pain: an analytical literature review of the smallest detectable difference, the minimal detectable change, and the minimal clinically important difference on the pain visual analog scale.

Authors:  Melissa E Stauffer; Stephanie D Taylor; Douglas J Watson; Paul M Peloso; Alan Morrison
Journal:  Int J Inflam       Date:  2011-05-05

5.  Psychometric properties of three single-item pain scales in patients with rheumatoid arthritis seen during routine clinical care: a comparative perspective on construct validity, reproducibility and internal responsiveness.

Authors:  Melanie Sendlbeck; Elizabeth G Araujo; Georg Schett; Matthias Englbrecht
Journal:  RMD Open       Date:  2015-12-18

6.  Comparative study of the effectiveness of a low-pressure hyperbaric oxygen treatment and physical exercise in women with fibromyalgia: randomized clinical trial.

Authors:  Ruth Izquierdo-Alventosa; Marta Inglés; Sara Cortés-Amador; Lucia Gimeno-Mallench; Núria Sempere-Rubio; Javier Chirivella; Pilar Serra-Añó
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-06-24       Impact factor: 5.346

7.  Magnet therapy for the relief of pain and inflammation in rheumatoid arthritis (CAMBRA): a randomised placebo-controlled crossover trial.

Authors:  Stewart J Richmond
Journal:  Trials       Date:  2008-09-12       Impact factor: 2.279

8.  Does the pain-protective GTP cyclohydrolase haplotype significantly alter the pattern or severity of pain in humans with chronic pancreatitis?

Authors:  Mark Lazarev; Janette Lamb; M Michael Barmada; Feng Dai; Michelle A Anderson; Mitchell B Max; David C Whitcomb
Journal:  Mol Pain       Date:  2008-11-17       Impact factor: 3.395

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.